(:JUNO)
Business Focus: N/A
Feb 21, 2018 07:30 am ET
Celgene Receives Antitrust Clearance for Juno Acquisition
Celgene Corporation (NASDAQ:CELG) today announced that the applicable
waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of
1976 ("HSR") with respect to the previously announced tender offer by
Celgene’s wholly owned subsidiary, Blue Magpie Corporation, for all
issued and outstanding shares of common stock of Juno Therapeutics, Inc.
(NASDAQ:JUNO) for $87.00 per share, net to the seller in cash, without
interest and less required withholding taxes, and subsequent merger of
Blue Magpie with Juno, expired at 11:59 p.m. ET on Febr
Feb 01, 2018 07:55 am ET
New Research: Key Drivers of Growth for Guess?, Acer Therapeutics, American National Insurance, J P Morgan Chase, Juno Therapeutics, and Allergan — Factors of Influence, Major Initiatives and Sustaine
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Guess?, Inc. (NYSE:GES), Acer Therapeutics, Inc....
Jan 25, 2018 02:10 pm ET
The Law Offices of Vincent Wong Reminds Investors of an Investigation of Juno Therapeutics, Inc. in Connection with the Sale of the Company to Celgene Corp.
The Law Offices of Vincent Wong are investigating the Board of Directors
of Juno Therapeutics, Inc. (NASDAQ: JUNO) for possible breaches of
fiduciary duty and other violations of state law in connection with the
sale of the Company to Celgene Corporation (NASDAQGS: CELG). Under the
terms of the deal, Juno shareholders will receive $87 for each Juno
share they own.
Jan 24, 2018 02:40 pm ET
The Law Offices of Vincent Wong Notifies Investors of an Investigation of Juno Therapeutics, Inc. in Connection with the Sale of the Company to Celgene Corp.
The Law Offices of Vincent Wong are investigating the Board of Directors
of Juno Therapeutics, Inc. (NASDAQ: JUNO) for possible breaches of
fiduciary duty and other violations of state law in connection with the
sale of the Company to Celgene Corporation (NASDAQGS: CELG). Under the
terms of the deal, Juno shareholders will receive $87 for each Juno
share they own.
Jan 24, 2018 11:40 am ET
WeissLaw LLP Investigates Juno Therapeutics Inc. Acquisition
NEW YORK, Jan. 24, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Juno Therapeutics Inc. ("JUNO" or the "Company") (NASDAQ: JUNO) in connection with the proposed acquisition of the Company by Celgene Corp. ("CELG") (NASDAQ: CELG). Under the terms of the acquisition agreement, the Company's shareholders will receive $87.00 in cash for each JUNO share they own.
Jan 23, 2018 12:20 pm ET
Jan 23, 2018 09:10 am ET
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Juno Therapeutics, Inc. to Celgene Corp. is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP:
Jan 22, 2018 02:55 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of Juno Therapeutics, Inc. - JUNO
NEW YORK, Jan. 22, 2018 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors and Officers of Juno Therapeutics, Inc. ("Juno" or the "Company") (NasdaqGS: JUNO) for possible breaches of fiduciary duty.
Jan 22, 2018 01:53 pm ET
JUNO THERAPEUTICS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes the Acquisition by Celgene Corporation May be Unfair to Shareholders
Former United States Securities and Exchange Commission attorney Willie
Briscoe is investigating potential claims against the Board of
Directors of Juno Therapeutics, Inc. (“Juno”) (NASDAQ: JUNO) concerning
the acquisition by Celgene Corporation. Under the terms of the
agreement, Juno shareholders will only receive $87.00 per Juno s
Jan 22, 2018 10:51 am ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Juno Therapeutics, Inc.
NEW YORK, Jan. 22, 2018 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Juno Therapeutics, Inc. (NASDAQ: JUNO) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Celgene Corporation. Stockholders will receive $87.00 for each share of Juno Therapeutics, Inc. that they hold. The transaction is valued at approximately $9 billion and is expected to close in the first quarter of 2018.
Jan 22, 2018 10:46 am ET
Jan 22, 2018 09:48 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Juno Therapeutics, Inc. to Celgene Corp. is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP:
Jan 22, 2018 07:49 am ET
Johnson Fistel, Announces Investigations of the Proposed Sales of Bioverativ Inc., and Juno Therapeutics, Inc.
SAN DIEGO, Jan. 22, 2018 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Bioverativ Inc., and Juno Therapeutics, Inc., as detailed below:
Jan 22, 2018 06:30 am ET
Celgene Corporation to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy
Celgene Corporation (NASDAQ:CELG) and Juno Therapeutics, Inc.
(NASDAQ:JUNO) today announced the signing of a definitive merger
agreement in which Celgene has agreed to acquire Juno. Under the terms
of the merger agreement, Celgene will pay $87 per share in cash, or a
total of approximately $9 billion, net of cash and marketable securities
acquired and Juno shares already owned by Celgene (approximately 9.7% of
outstanding shares). The transaction was approved by the boards of
directors of both companies.
Jan 19, 2018 10:50 pm ET
JUNO THERAPEUTICS INVESTIGATION by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. - JUNO
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a
partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces
that KSF has commenced an investigation into Juno Therapeutics, Inc.
(NasdaqGS: JUNO).
Jan 17, 2018 08:31 am ET
Is it time to buy stock in bluebird bio Inc., Ford, The Goldman Sachs Group and Juno Therapeutics Inc?
CHICAGO, Jan. 17, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLUE, F, GS and JUNO.
Jan 12, 2018 09:50 pm ET
JUNO THERAPEUTICS INVESTIGATION BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. - JUNO
NEW ORLEANS, Jan. 12, 2018 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Juno Therapeutics, Inc. (NasdaqGS: JUNO).
Jan 05, 2018 10:50 pm ET
JUNO THERAPEUTICS INVESTIGATION by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. - JUNO
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a
partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces
that KSF has commenced an investigation into Juno Therapeutics, Inc.
(NasdaqGS: JUNO).
Jan 05, 2018 04:50 pm ET
Juno Therapeutics Names Cindy Elkins as Chief Information Officer
Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company
developing innovative cellular immunotherapies for the treatment of
cancer, today announced the appointment of Cindy Elkins as Chief
Information Officer (CIO). Elkins will report to Hans Bishop, Juno’s
President and CEO.
Jan 03, 2018 04:05 pm ET
Juno Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced that it will
webcast its presentation at the 36th Annual J.P. Morgan
Healthcare Conference at 4:00 p.m. PT on Tuesday, January 9, 2018. The
presentation will feature a business overview and update by Hans Bishop,
Juno’s President and Chief Executive Officer.
Dec 20, 2017 07:00 am ET
Juno Therapeutics and Thermo Fisher Scientific Announce CAR T Manufacturing Partnership
WALTHAM, Mass., Dec. 20, 2017 /PRNewswire/ -- Juno Therapeutics (NASDAQ: JUNO) and Thermo Fisher Scientific have entered into a partnership for Juno to use Thermo Fisher's Cell Therapy Systems (CTS) activation reagents in the manufacturing of its chimeric antigen receptor T cell (CAR T) therapies.
Dec 12, 2017 04:02 pm ET
Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH
Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company
developing innovative cellular immunotherapies for the treatment of
cancer, today highlighted presentations and data from the 59th American
Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta,
Georgia, December 9-12, 2017.
Dec 12, 2017 08:31 am ET
Should you buy or sell Advanced Micro Devices, Alibaba, Juno Therapeutics Inc, Nike or Overstock.com?
CHICAGO, Dec. 12, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, BABA, JUNO, NKE, and OSTK.
Dec 11, 2017 07:00 am ET
Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company
developing innovative cellular immunotherapies for the treatment of
cancer, and Celgene Corporation (NASDAQ: CELG) today released additional
data from the TRANSCEND study of JCAR017 (lisocabtagene maraleucel;
liso-cel) in patients with relapsed or refractory (r/r) aggressive
B-cell non-Hodgkin lymphoma (NHL) in a presentation at the 59th
American Society of Hematology (ASH) Annual Meeting and Exposition.
Dec 09, 2017 02:00 pm ET
Juno Therapeutics Highlights Key Translational Insights with JCAR017 in Patients with DLBCL
Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company
developing innovative cellular immunotherapies for the treatment of
cancer, today presented new translational insights on clinical outcomes
with its investigational CAR T product candidate JCAR017 at the 59th
American Society of Hematology (ASH) Annual Meeting and Exposition.
Dec 06, 2017 09:00 am ET
Juno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma S
Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company
developing innovative cellular immunotherapies for the treatment of
cancer, today announced three license agreements to advance its program
in multiple myeloma using gamma secretase inhibitors (GSIs) in
combination with BCMA-directed CAR T cells.
Nov 28, 2017 07:35 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Juno Therapeutics, Abbott Laboratories, Freeport-McMoran, HP, The Trade Desk, and Platform Specialty Products — New Research Emphasi
NEW YORK, Nov. 28, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Juno Therapeutics, Inc. (NASDAQ:JUNO), Abbott Laboratories...
Nov 27, 2017 09:00 am ET
Juno Therapeutics Appoints Ann L. Lee as Executive Vice President of Technical Operations and Patrick Y. Yang as Executive Vice President, Senior Advisor to the CEO
Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company
developing innovative cellular immunotherapies for the treatment of
cancer, today announced the appointment of Ann L. Lee, Ph.D., as
Executive Vice President of Technical Operations. Dr. Patrick Y. Yang
will assume the role of Executive Vice President, Senior Advisor to the
CEO. Both will report to Hans Bishop, President and CEO, and work to
further advance Juno as a global leader in T cell engineering and
manufacturing.
Nov 13, 2017 07:20 pm ET
Robbins Arroyo LLP: Juno Therapeutics, Inc. (JUNO) Misled Shareholders According to a Recently Filed Shareholder Derivative Lawsuit
Shareholder rights law firm Robbins Arroyo LLP announces
that a shareholder derivative complaint was filed on behalf of Juno
Therapeutics, Inc. (NasdaqGS: JUNO). The complaint is brought against
certain current and former officers and directors for alleged breaches
of fiduciary duti
Nov 06, 2017 04:05 pm ET
Juno Therapeutics to Present at November 2017 Investor Conferences
Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will
webcast its presentations at two investor conferences in November. The
presentations will feature a business overview and update by Steve Harr,
Juno’s Chief Financial Officer and Head of Corporate Development.
Nov 01, 2017 04:05 pm ET
Juno Therapeutics Reports Third Quarter 2017 Financial Results
Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company
developing innovative cellular immunotherapies for the treatment of
cancer, today reported financial results and business highlights for the
third quarter 2017.
Nov 01, 2017 09:11 am ET
Juno Therapeutics to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH
Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company
developing innovative cellular immunotherapies for the treatment of
cancer, today announced that 15 abstracts detailing updated clinical and
preclinical results from the company and its collaborators will be
presented at the 59th American Society of Hematology (ASH)
Annual Meeting. Senior executives will also review results and provide
an update on Juno’s clinical development program at an analyst and
investor event, which will also be available via webcast.
Oct 31, 2017 07:44 pm ET
JUNO Investor Alert: Kyros Law is Investigating Legal Claims on Behalf of JUNO THERAPEUTICS, INC. (NASDAQ: JUNO) Investors
BOSTON, Oct. 31, 2017 /PRNewswire/ -- Kyros Law Offices is alerting investors of JUNO THERAPEUTICS, INC. (NASDAQ: JUNO) that it is investigating legal claims against the company for possible securities fraud violations committed by JUNO THERAPEUTICS, INC. (NASDAQ: JUNO).
Oct 25, 2017 04:05 pm ET
Juno Therapeutics to Report Third Quarter 2017 Financial Results on Wednesday, November 1
Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results
for the third quarter 2017 on Wednesday, November 1, 2017, after the
close of U.S.-based financial markets. Following the announcement, Juno
management will host a conference call and live webcast to provide a
business update and discuss financial results beginning at 1:30 p.m.
Pacific Time (PT) / 4:30 p.m. Eastern Time (ET).
Oct 24, 2017 01:50 pm ET
Robbins Arroyo LLP Is Investigating the Officers and Directors of Juno Therapeutics, Inc. (JUNO) on Behalf of Shareholders
Shareholder rights law firm Robbins Arroyo LLP is investigating
whether certain officers and directors of Juno Therapeutics, Inc.
(NasdaqGS: JUNO) breached their fiduciary duties to shareholders. Juno,
a biopharmaceutical company, engages in developing cell-based cancer
immunoth
Oct 18, 2017 09:00 am ET
Trianni and Juno Therapeutics Sign Licensing Agreement for Use of Trianni Transgenic Mouse Platform
SAN FRANCISCO, Oct. 18, 2017 /PRNewswire/ -- Trianni, Inc. ("TRIANNI") today announced that Juno Therapeutics (NASDAQ: JUNO) has entered into a license agreement for The Trianni Mouse™, a best-in-class monoclonal antibody discovery platform. Juno intends to use The Trianni Mouse with its proprietary high throughput, single cell sequencing technology and direct-to-CAR screening to rapidly identify fully-human binders for conversion to chimeric antigen receptors in its engineered T cell programs.
Oct 03, 2017 08:01 pm ET
Sep 18, 2017 06:30 pm ET
Stull, Stull & Brody Announces Lawsuit Against Certain Officers and Directors of Juno Therapeutics, Inc. (NASDAQ: JUNO)
NEW YORK, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Stull, Stull & Brody announces that a lawsuit was commenced in the United States District Court for the Western District of Washington against certain executive officers and members of the Board of Directors of Juno Therapeutics, Inc. (“Juno” or the “Company”) (NASDAQ:JUNO), pursuant to the Securities Exchange Act of 1934 (“Exchange Act”) and applicable state laws....
Aug 28, 2017 10:31 am ET
Options Trader Alert: Covered-call reports released for Caterpillar Inc., Juno Therapeutics Inc, Kite Pharma, Southwest Airlines Co. and Ulta Salon Cosmetics & Fragrance Inc.
CHICAGO, Aug. 28, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAT, JUNO, KITE, LUV, and ULTA.
Aug 18, 2017 11:50 pm ET
JUNO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Juno Therapeutics, Inc. - JUNO
NEW ORLEANS, Aug. 18, 2017 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Juno Therapeutics, Inc. (NasdaqGS: JUNO).
Aug 09, 2017 04:01 pm ET
Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment
CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it achieved a second milestone under its collaboration with Juno Therapeutics, Inc. (NASDAQ:JUNO). The most recent milestone results from the Company’s technical progress towards overcoming the tumor microenvironment in a research program to create engineered T cells with chimeric antigen receptors (CAR) and T cell receptors (TCR) to treat cancer. Improving the ability of T cells to overcome the tumor microenvironment may expand the range of cancers ...
Aug 08, 2017 09:00 am ET
Executives of Juno Therapeutics Under Investigation
SAN FRANCISCO, Aug. 8, 2017 /PRNewswire/ -- Shareholder and consumer rights law firm Schubert Jonckheer & Kolbe LLP has launched an investigation into whether certain officers and directors of Juno Therapeutics, Inc. ("Juno" or the "Company") (NASDAQ: JUNO) breached their fiduciary duties to Juno and its shareholders by exposing Juno to civil liability for failing to disclose patient deaths in the Phase II/ROCKET trial of its leading product candidate, JCAR015, during the period June 24, 2016 to November 22, 2016.
Jul 14, 2017 10:31 am ET
InvestorsObserver releases covered-call reports for Alibaba, Citigroup, JP Morgan Chase, Juno Therapeutics Inc and Wells Fargo & Co.
CHICAGO, July 14, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BABA, C, JPM, JUNO, and WFC.
Jun 08, 2017 10:31 am ET
Investors: Covered Call reports for Alcoa, bluebird bio Inc., Juno Therapeutics Inc, TG Therapeutics and XPO Logistics Inc include trade ideas that offer returns of 25% or more!
CHICAGO, June 8, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AA, BLUE, JUNO, TGTX, and XPO.
Apr 27, 2017 10:31 am ET
Investors: Option Trade reports for Juno Therapeutics Inc, Lumber Liquidators, Las Vegas Sands, Twitter and US Steel.
CHICAGO, April 27, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JUNO, LL, LVS, TWTR, and X.
Nov 01, 2016 10:31 am ET
Learn how to target a 20% return on Bristol-Myers Squibb, or get option-trade ideas on Alcoa, JC Penney, Sears Holdings and Juno Therapeutics Inc or any stock you choose
CHICAGO, Nov. 1, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AA, BMY, JCP, JUNO, and SHLD.
Oct 11, 2016 10:31 am ET
First Solar, Baozun Inc., Deere, Tenet Healthcare, and Juno Therapeutics Inc and more offer option-trading opportunities that offer returns of more than 20%
CHICAGO, Oct. 11, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BZUN, DE, FSLR, JUNO, and THC.
Sep 26, 2016 10:30 am ET
Learn how to target a 20% return on Twilio Inc., or get option-trade ideas on Smith & Wesson, Juno Therapeutics Inc, Signet Jewelers Limited and Valero Energy or any stock you choose
CHICAGO, Sept. 26, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JUNO, SIG, SWHC, TWLO, and VLO.
Sep 12, 2016 11:15 am ET
DEADLINE ALERT & UPDATED CLASS PERIOD - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Juno Therapeutics, Inc. (JUNO) & Lead Plaintiff Deadline: September 12, 2016
NEW YORK, Sept. 12, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed against Juno Therapeutics, Inc. ("Juno" or the "Company") (NASDAQ: JUNO) and certain of its officers, in the United States District Court Western District of Washington. This class action has been expanded to include purchasers of Juno's securities between May 9, 2016 and July 7, 2016, inclusive (the "Class Period").
Sep 09, 2016 10:31 am ET
Bank of America, Tesaro Inc., Juno Therapeutics Inc, ACADIA Pharmaceuticals, and Canadian Solar and more offer option-trading opportunities that offer returns of more than 20%
CHICAGO, Sept. 9, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACAD, BAC, CSIQ, JUNO, and TSRO.
Sep 08, 2016 03:25 pm ET
Important Shareholder Update And Deadline Alert: Expanded Class Period In Shareholder Class Action Filed Against Juno Therapeutics, Inc. - JUNO
RADNOR, Pa., Sept. 8, 2016 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts shareholders of Juno Therapeutics, Inc. (Nasdaq: JUNO) ("Juno" or the "Company") that the class period in the securities fraud lawsuit filed against the Company and certain of its executive officers has been expanded to include purchasers of Juno's securities between May 9, 2016 and July 7, 2016, inclusive (the "Class Period").
Sep 07, 2016 09:30 am ET
HB ALERT: Hagens Berman Reminds Juno Therapeutics Inc. (NASDAQ: JUNO) Investors of September 12, 2016 Lead Plaintiff Deadline
SAN FRANCISCO, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP reminds investors in Juno Therapeutics Inc. (NASDAQ:JUNO) that the Lead Plaintiff Deadline is September 12, 2016....
Sep 06, 2016 11:00 am ET
UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Juno Therapeutics Inc. and a Lead Plaintiff Deadline of September 12, 2016 -- JUNO
NEW YORK, Sept. 06, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington, Seattle Division on behalf of investors who purchased Juno Therapeutics Inc. (NASDAQ:JUNO) securities between June 4, 2016 and July 7, 2016....
Sep 02, 2016 08:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Juno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – JUNO
NEW YORK, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Juno Therapeutics, Inc. (“Juno” or the “Company”) (NASDAQ:JUNO) and certain of its officers. The class action, filed in United States District Court, Western District of Washington, and docketed under 16-cv-01083, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Juno securities between June 4, 2016 and July 7, 2016 inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged v...
Sep 02, 2016 10:38 am ET
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Juno Therapeutics Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 12, 2016 – JUNO
NEW YORK, Sept. 02, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:...
Sep 02, 2016 10:00 am ET
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Juno Therapeutics, Inc. (JUNO) & Lead Plaintiff Deadline: September 12, 2016
NEW YORK, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States Disctirct Court Western District of Washington on behalf of those who purchased shares of Juno Therapeutics, Inc. (“Juno” or the “Company”) (NASDAQ:JUNO) and certain of its officers, during the period between June 4, 2016 and June 7, 2016, inclusive (the “Class Period”)....
Aug 30, 2016 09:06 am ET
Purcell Julie & Lefkowitz LLP Is Investigating Juno Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, Aug. 30, 2016 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Juno Therapeutics, Inc. (NASDAQ: JUNO).
Aug 26, 2016 10:07 pm ET
JUNO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Juno
NEW ORLEANS, Aug. 26, 2016 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 12, 2016 to file lead plaintiff applications in a securities class action lawsuit against Juno Therapeutics, Inc. (Nasdaq:JUNO), if they purchased the Company’s securities between June 4, 2016 and July 7, 2016, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Washington....
Aug 22, 2016 10:15 am ET
Lawsuit for Investors in shares of Juno Therapeutics Inc announced by Shareholders Foundation
SAN DIEGO, Aug. 22, 2016 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in Washington on behalf of certain purchasers of shares of Juno Therapeutics Inc (NASDAQ:JUNO) over alleged Securities Laws Violations by Juno Therapeutics. The lawsuit seeks to recover damages for certain NASDAQ:JUNO investors. ...
Aug 19, 2016 12:04 pm ET
JUNO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Juno Therapeutics Inc. and a Lead Plaintiff Deadline of September 12, 2016
NEW YORK, Aug. 19, 2016 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington, Seattle Division on behalf of investors who purchased Juno Therapeutics Inc. (NASDAQ: JUNO) securities between June 4, 2016 and July 7, 2016.
Aug 10, 2016 09:00 am ET
Kessler Topaz Meltzer & Check, LLP Reminds Juno Therapeutics, Inc. Shareholders of Important Deadline in Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed in the United States District Court for the Western District of Washington against Juno Therapeutics, Inc. (NASDAQ: JUNO) ("Juno"...
Aug 08, 2016 04:23 pm ET
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Juno Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Clas
STEVENSON, Md., Aug. 08, 2016 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf of purchasers of Juno Therapeutics, Inc. (Nasdaq:JUNO) (“Juno” or the “Company”) securities during the period between June 4, 2016 and July 7, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until September 12, 2016 to seek appointment as lead plaintiff....
Aug 05, 2016 09:30 am ET
Hagens Berman Advises Juno Therapeutics Inc. (NASDAQ: JUNO) Investors of September 12, 2016 Lead Plaintiff Deadline
SAN FRANCISCO, Aug. 05, 2016 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP advises investors in Juno Therapeutics Inc. (NASDAQ:JUNO) that the Lead Plaintiff Deadline is September 12, 2016....
Aug 05, 2016 09:00 am ET
JUNO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Juno Therapeutics Inc. and a Lead Plaintiff Deadline of September 12, 2016
NEW YORK, Aug. 05, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington, Seattle Division on behalf of investors who purchased Juno Therapeutics Inc. (NASDAQ:JUNO) securities between June 4, 2016 and July 7, 2016....
Aug 01, 2016 10:59 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Juno Therapeutics Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of September 12, 2016 – JUNO
NEW YORK, Aug. 01, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:...
Jul 30, 2016 01:01 am ET
Shareholder Rights Law Firm Johnson & Weaver, LLP Initiates Investigations of; Oracle Corporation, K12 Inc., Juno Therapeutics, Inc., Albany Molecular Research Inc. and Insmed Incorporated; Encourages
SAN DIEGO, July 30, 2016 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential claims against Oracle Corporation, K12 Inc., Juno Therapeutics, Inc., Albany Molecular Research Inc. and Insmed Incorporated, as detailed below:
Jul 29, 2016 11:07 pm ET
JUNO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Juno
NEW ORLEANS, July 29, 2016 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 12, 2016 to file lead plaintiff applications in a securities class action lawsuit against Juno Therapeutics, Inc. (NasdaqGS: JUNO), if they purchased the Company's securities between June 4, 2016 and July 7, 2016, inclusive (the "Class Period"). This action is pending in the United States District Court for the Western District of Washington.
Jul 29, 2016 02:47 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Juno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – JUNO
NEW YORK, July 29, 2016 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Juno Therapeutics, Inc. (“Juno” or the “Company”) (NASDAQ:JUNO) and certain of its officers. The class action, filed in United States District Court, Western District of Washington, and docketed under 16-cv-01083, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Juno securities between June 4, 2016 and July 7, 2016 inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged vi...
Jul 22, 2016 10:07 pm ET
JUNO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Juno
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 12, 2016 to file lead plaintiff applications in a securities class action lawsuit...
Jul 22, 2016 06:09 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Juno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - JUNO
NEW YORK, July 22, 2016 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Juno Therapeutics, Inc. ("Juno" or the "Company") (NASDAQ: JUNO) and certain of its officers. The class action, filed in United States District Court, Western District of Washington, and docketed under 16-cv-01083, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Juno securities between June 4, 2016 and July 7, 2016 inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violat
Jul 22, 2016 09:52 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Juno Therapeutics Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 12, 2016 -- JUNO
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Juno Therapeutics, Inc. ("Juno") (NASDAQ: JUNO) between June 4, 2016 and July 7, 2016. You are hereby...
Jul 21, 2016 11:03 am ET
Scott + Scott, LLP Notifies Investors of Juno Therapeutics, Inc. (Nasdaq: JUNO) Securities Lawsuit, Encourages Investors With Losses to Contact Firm
NEW YORK, July 21, 2016 (GLOBE NEWSWIRE) -- Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, notifies investors that a securities lawsuit has been filed on behalf of investors in Juno Therapeutics, Inc. (Nasdaq:JUNO). Juno investors are encouraged to contact Scott + Scott at (866) 326-5057 or email [email protected] to discuss their legal rights. ...
Jul 20, 2016 09:30 am ET
INVESTOR ALERT: Hagens Berman Alerts Juno Therapeutics Inc. (NASDAQ: JUNO) Investors Insider Selling Securities Class Action and September 12, 2016 Lead Plaintiff Deadline
SAN FRANCISCO, July 20, 2016 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in Juno Therapeutics Inc. (NASDAQ:JUNO) that a securities class action is pending in the United States District Court for the Western District of Washington and the Lead Plaintiff Deadline is September 12, 2016....
Jul 18, 2016 10:07 pm ET
JUNO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Juno
NEW ORLEANS, July 18, 2016 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 12, 2016 to file lead plaintiff applications in a securities class action lawsuit against Juno Therapeutics, Inc. (Nasdaq:JUNO), if they purchased the Company’s securities between June 4, 2016 and July 7, 2016, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Washington....
Jul 18, 2016 03:38 pm ET
IMPORTANT NOTICE TO SHAREHOLDERS: Brower Piven Notifies Shareholders of Securities Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Juno Therapeut
STEVENSON, Md., July 18, 2016 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf of purchasers of Juno Therapeutics, Inc. (Nasdaq:JUNO) (“Juno” or the “Company”) securities during the period between June 4, 2016 and July 7, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until September 12, 2016 to seek appointment as lead plaintiff....
Jul 18, 2016 12:48 pm ET
JUNO INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Juno Therapeutics Inc. and a Lead Plaintiff Deadline of September 12, 2016
NEW YORK, July 18, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington, Seattle Division on behalf of investors who purchased Juno Therapeutics Inc. (NASDAQ:JUNO) securities between June 4, 2016 and July 7, 2016....
Jul 15, 2016 08:15 pm ET
Juno Therapeutics, Inc. and Its CEO Sued for Securities Fraud by Block & Leviton LLP
BOSTON, July 15, 2016 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (“Juno” or the “Company”) (NASDAQ:JUNO) and its chief executive officer, Hans E. Bishop, were named as defendants in a lawsuit filed earlier this week by Block & Leviton LLP and Tousley Brain Stephens PLLC alleging that they violated the federal securities laws. ...
Jul 15, 2016 04:47 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Juno Therapeutics, Inc. and Certain Officers – JUNO
NEW YORK, July 15, 2016 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Juno Therapeutics, Inc. (“Juno” or the “Company”) (NASDAQ:JUNO) and certain of its officers. The class action, filed in United States District Court, Western District of Washington, and docketed under 16-cv-01083, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Juno securities between June 4, 2016 and July 7, 2016 inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged vio...
Jul 15, 2016 03:07 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Juno Therapeutics, Inc.
WILMINGTON, Del., July 15, 2016 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.:...
Jul 15, 2016 02:00 am ET
Vernalis Notes the Acquisition of RedoxTherapies by Juno Therapeutics
Vernalis PLC (LSE: VER) (OTC PINK: VNLPY)
Jul 14, 2016 02:56 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Juno Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 12, 2016 - JUNO
NEW YORK, July 14, 2016 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP:
Jul 14, 2016 02:39 pm ET
Shareholder Class Action Filed Against Juno Therapeutics, Inc. - Juno
RADNOR, Pa., July 14, 2016 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against Juno Therapeutics, Inc. (Nasdaq: JUNO) ("Juno" or the "Company") on behalf of purchasers of the Company's securities between June 4, 2016 through July 7, 2016, inclusive (the "Class Period").
Jul 13, 2016 03:49 pm ET
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Juno Therapeutics, Inc.
On July 12, 2016, a class action lawsuit was filed in the United States District Court for the Western District of Washington against Juno Therapeutics, Inc. (NASDAQ: JUNO). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is June 4, 2016 through July 7, 2016.
Jul 13, 2016 03:43 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Juno Therapeutics Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 12, 2016 – JUNO
NEW YORK, July 13, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:...
Jul 13, 2016 11:18 am ET
Juno Therapeutics, Inc. and Its CEO Sued for Securities Fraud
BOSTON, July 13, 2016 /PRNewswire/ -- Juno Therapeutics, Inc. ("Juno" or the "Company") (NASDAQ: JUNO) and its chief executive officer, Hans E. Bishop, were named as defendants in a lawsuit filed yesterday by Block & Leviton LLP and Tousley Brain Stephens PLLC alleging that they violated the federal securities laws.
Jul 11, 2016 11:15 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Juno Therapeutics, Inc. (JUNO)
NEW YORK, July 11, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Juno Therapeutics, Inc. ("Juno" or the "Company") (NASDAQ: JUNO). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at [email protected] or 212-697-6484.
Jul 08, 2016 10:09 am ET
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Juno Therapeutics Inc. - JUNO
NEW YORK, July 8, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Juno Therapeutics Inc. ("Juno" or the Company) (NASDAQ: JUNO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Jul 07, 2016 10:29 pm ET
Block & Leviton Investigates Juno Therapeutics After Announcement Of Previously Unreported Patient Deaths In Clinical Trial
BOSTON, July 7, 2016 /PRNewswire-USNewswire/ -- Shares in Juno Therapeutics Inc. ("Juno" or the "Company") (NASDAQ: JUNO) have plunged approximately 28%, after the Company disclosed that two patients died "last week" and a third died in May in clinical trials of its immuno-oncology therapeutic JCAR15. All three patients died of a cerebral edema after receiving a drug called fludarabine as part of the pre-conditioning regimen. A number of previously published clinical articles have identified a possible link between fludarabine and neurotoxicity.
May 04, 2016 07:30 am ET
Editas Medicine Achieves Milestone under its Collaboration with Juno Therapeutics
CAMBRIDGE, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it has achieved a $2.5 million milestone under its collaboration with Juno Therapeutics, Inc. (NASDAQ:JUNO) for technical progress in a research program to create engineered T cells with chimeric antigen receptors (CAR) and T cell receptors (TCR) to treat cancer. Editas and Juno are pursuing three research programs utilizing Editas’ genome editing technologies, including CRISPR/Cas9, with Juno’s CAR and TCR technologies. Under the terms of the c...
Apr 07, 2016 05:30 pm ET
Juno Therapeutics and WuXi AppTec Announce New Company to Develop Novel Cell-Based Cancer Immunotherapies in China
SEATTLE and SHANGHAI, April 7, 2016 /PRNewswire/ -- Juno Therapeutics (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, and WuXi AppTec, a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that they have started a new company in China. JW Biotechnology (Shanghai) Co., Ltd's mission is to build China's leading cell therapy company by leveraging Juno's world-class chimeric antigen receptor (CAR) and T
Mar 14, 2016 10:31 am ET
Covered Call Alerts For Disney, Juno Therapeutics Inc, Relypsa, Bojangles Inc. and Terraform Power Released By InvestorsObserver
CHICAGO, March 14, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DIS, JUNO, RLYP, BOJA and TERP.
Feb 26, 2016 09:31 am ET
Covered Call Alerts For Kinder Morgan, Juno Therapeutics Inc, Weight Watchers, Dominos Pizza and US Steel Released By InvestorsObserver
CHICAGO, Feb. 26, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KMI, JUNO, WTW, DPZ and X.
Feb 16, 2016 09:31 am ET
Covered Call Alerts For Kinder Morgan, Google, Intrexon, Canadian Solar and Juno Therapeutics Inc Released By InvestorsObserver
CHICAGO, Feb. 16, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KMI, GOOGL, XON, CSIQ and JUNO.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.